- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01795092
A Study Assessing the Impact of Dermatology Consultation in Patients Presenting With Possible Cellulitis
A Randomized-controlled Study to Assess the Impact of Dermatology Consultations on Reducing Admissions for Patients Presenting to Internal Medicine Clinics for Possible Cellulitis
Study Overview
Detailed Description
Patients to be enrolled in the study will be those that present to outpatient internal medicine clinic and are identified by primary care physicians as having pain, redness, and swelling of the skin that the physician believes may represent cellulitis. Patient recruitment will occur at five Massachusetts General Hospital (MGH) outpatient internal medicine clinical sites: Medical Walk-In, Internal Medicine Associates, Bulfinch Medical Group, Senior Health, and Women's health. Patients with abnormal vital signs will be excluded, specifically systolic blood pressure <90 mmHg, diastolic blood pressure <80 mmHg, heart rate greater than 90 beats per minute or less than 50 beats per minute, respiratory rate greater than 20, or temperature >100.5 F. In addition, any patients with a history of transplantation must be more than six months after initial transplant with no treated episodes of acute rejection in the last 90 days, no use of antithymocyte globulin or campath to treat rejection in the last 6 months, or more than 20 mg/day of prednisone for more than 30 days.
Once a patient is identified with potential cellulitis who is a candidate for outpatient treatment, the primary care physician will then approach them regarding their interest in entering our study. Patients will be randomized during this initial presentation to their primary care physician. The patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician"s office and will be sent to the Emergency Department or discharged home with outpatient dermatology follow-up in two to three days to assess for improvement in their condition versus no change or worsening that requires transfer to the Emergency Department. Patients who are evaluated by a dermatologist and who require hospitalization will have their transition to the Emergency Department managed by the dermatologist with notification of the patient"s PCP. These patients who have follow-up in dermatology clinic will not require a follow-up visit with their primary care physician. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the electronic medical record for the subjects" medical records. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic. A medical record review will be performed for patients who are randomized to the treatment group two weeks after initial evaluation at the internal medicine clinic.
Those in the control group who do not obtain a dermatology evaluation will follow primary care recommendations alone and will also have chart review two weeks later to assess for admission versus discharge home from clinic and outcome. In the control group, the need for additional clinical follow-up will be at the primary care physician"s discretion. These patients will receive a followup telephone call to confirm the final outcome of their condition two weeks after their visit to internal medicine clinic. The data sets generated from the treatment and control groups will then be compared to look for differences in hospital admission rates. For the treatment arm of the study, this data will be obtained during the follow-up visit and the medical record review. For the control arm, this will be obtained during both the medical record review and the follow-up phone call. The goal of this data collection is to determine what the final outcome is for patients in both groups in terms of need for hospital admission.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to understand and sign informed consent.
- Able to complete study and comply with study procedures.
- Presumed clinical diagnosis of cellulitis by primary care physician
Exclusion Criteria:
- Have a known postoperative site infection or abscess
- Have a human/animal bite
- Have known osteomyelitis
- Have a hardware/line infection
- Are under the age of 18
- Have a history of transplantation less than six months after initial transplant and/or if they have had an episode of acute rejection in the last 90 days
- Known use of antithymocyte globulin or campath in the last 6 months or more than 20 mg/day of prednisone for more than 30 days
- Are a known prisoner.
- Are decisionally-impaired.
- Have abnormal vital signs defined as systolic blood pressure <90 mmHg, diastolic blood pressure <80 mmHg, heart rate greater than 90 beats per minute or less than 50 beats per minute, respiratory rate greater than 20, or temperature > 100.5 F.
- Are known to be pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider.
We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
|
|
Experimental: Dermatology consultation
Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition.
Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist.
Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures.
A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
|
A dermatology consultation will be conducted on patients randomized to this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of Hospital admission
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients antibiotic was prescribed, type, dose, and duration of antibiotic prescribed and adverse events related to antibiotic usage.
Time Frame: 3 months
|
We will be recording whether an antibiotic was prescribed, which antibiotic was used, the duration of treatment, the dosage of antibiotic, the cost of the antibiotic, and any adverse events related to antibiotic usage.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniela Kroshinsky, MD, MPH, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008A058574 (Other Grant/Funding Number: Dermatology Foundation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulitis
-
McGill University Health Centre/Research Institute...CompletedCellulitis | Cellulitis of Leg | Cellulitis of ArmCanada
-
University of SouthamptonUniversity of Nottingham; Norfolk and Norwich University Hospitals NHS Foundation... and other collaboratorsNot yet recruitingCellulitis of Leg
-
Hillel Yaffe Medical CenterUnknown
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUncomplicated Outpatient CellulitisCanada
-
University of SussexCompletedCellulitis | Cellulitis of Leg | Antibiotic DurationUnited Kingdom
-
University Hospital Plymouth NHS TrustTerminated
-
BTL Industries Ltd.CompletedCellulitis | Cellulite | Cellulitis of LegUnited States
-
InMode MD Ltd.RecruitingCellulitis of LegUnited States
-
Cairo UniversityRecruitingFibrosis | Lower Limb Lymphedema | Cellulitis of LegEgypt
-
Minia UniversityCompletedEndophthalmitis and Orbital CellulitisEgypt
Clinical Trials on Dermatology Consultation
-
University Hospital, LilleRecruitingAtopic DermatitisFrance
-
Massachusetts General HospitalDermatology FoundationActive, not recruitingCellulitisUnited States
-
Elucid Labs Inc.UnknownMelanoma (Skin) | Squamous Cell Carcinoma of the Skin | Basal Cell Carcinoma of the SkinCanada
-
University of Southern CaliforniaIcahn School of Medicine at Mount Sinai; Brigham and Women's HospitalActive, not recruiting
-
Jordi Gol i Gurina FoundationInstitut Català de la Salut; iDoc24Completed
-
Pyoeng Gyun ChoeTerminatedSkin DiseasesKorea, Republic of
-
Centro Studi GisedCompletedMelanoma | Warts | Tinea | Actinic Keratosis | Herpes Zoster | Basal Cell Carcinoma | Erysipelas | Squamous Cell Carcinoma | Impetigo | Molluscum ContagiosumItaly
-
Centre Hospitalier Universitaire de NiceCompleted
-
Central Hospital, Nancy, FranceUnknown
-
University of Southern DenmarkUniversity of Copenhagen; University of Aarhus; Region North DenmarkCompletedQuality of Life | Life StyleDenmark